The<unk>  variant (B.1.617.2) is a variant of SARS-CoV-2, the virus that causes COVID-19. It was first detected in India in late 2020. The<unk>  variant was named on 31 May 2021 and had spread to over 179 countries by 22 November 2021. The World Health Organization (WHO) indicated in June 2021 that the<unk>  variant was becoming the dominant strain globally. It has mutations in the gene encoding the SARS-CoV-2 spike protein causing the substitutions T478K, P681R and L452R, which are known to affect transmissibility of the virus as well as whether it can be neutralised by antibodies for previously circulating variants of the COVID-19 virus. It is thought to be one of the most transmissible respiratory viruses known. In August 2021, Public Health England (PHE) reported secondary attack rate in household contacts of non-travel or unknown cases for<unk>  to be 10.8% vis-à-vis 10.2% for the Alpha variant; the case fatality rate for those 386,835 people with<unk>  is 0.3%, where 46% of the cases and 6% of the deaths are unvaccinated and below 50 years old. Immunity from previous recovery or COVID-19 vaccines are effective in preventing severe disease or hospitalisation from infection with the variant. On 7 May 2021, PHE changed their classification of lineage B.1.617.2 from a variant under investigation (VUI) to a variant of concern (VOC) based on an assessment of transmissibility being at least equivalent to B.1.1.7 (Alpha variant); the UK's SAGE using May data estimated a "realistic" possibility of being 50% more transmissible. On 11 May 2021, the WHO also classified this lineage VOC, and said that it showed evidence of higher transmissibility and reduced neutralisation. On 15 June 2021, the Centers for Disease Control and Prevention (CDC) declared<unk>  a variant of concern. The variant is thought to be partly responsible for India's deadly second wave of the pandemic beginning in February 2021. It later contributed to a third wave in Fiji, the United Kingdom and South Africa, and the WHO warned in July 2021 that it could have a similar effect elsewhere in Europe and Africa. By late July, it had also driven an increase in daily infections in parts of Asia, the United States, Australia, and New Zealand. Yet another COVID variant, Omicron, followed.
SARS-CoV-2 Delta variant
SARS-CoV-2 Omicron variant
SARS-CoV-2 Epsilon variant
SARS-CoV-2 Mu variant
SARS-CoV-2 Gamma variant
SARS-CoV-2 Eta variant
SARS-CoV-2 Lambda variant
SARS-CoV-2 Alpha variant